FOXO4-DRI — the senolytic peptide.

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells, triggering their selective apoptosis. It is one of the most expensive research peptides on PeptideCompare, and one of the most scientifically interesting in longevity research.

Last reviewed: 2026-06-24

How FOXO4-DRI targets senescent cells

Senescent cells — "zombie cells" that have stopped dividing but refuse to die — accumulate with age and secrete pro-inflammatory signals (SASP). In healthy cells, FOXO4 and p53 interact to maintain survival. FOXO4-DRI is a peptide that disrupts this interaction specifically in senescent cells, where this survival pathway is abnormally active, triggering apoptosis selectively. Normal cells are largely unaffected.

The original Nature Medicine paper (2017, van Deursen group) showed dramatic rejuvenation effects in naturally aged and chemotherapy-induced senescence mouse models — improved fitness, fur density, and renal function. This generated enormous research interest.

EVIDENCE SUMMARY

STRONG (ANIMAL)

Senescent cell clearance — Robust mouse data showing selective senescent cell apoptosis. Rejuvenation effects in multiple organ systems in aged rodents.

HUMAN: NONE

Human data — No published human clinical trials as of mid-2026. All human interest is extrapolated from animal research.

⚠ FOXO4-DRI is one of the highest-risk research peptides by mechanism. A peptide that selectively induces cell death — even targeting senescent cells — warrants extreme caution. No human safety data exists. Animal models use carefully controlled doses. Research compound only.

Compare FOXO4-DRI prices across EU suppliers

€179–215 per 10mg · 3 EU vendors currently tracked

FOXO4-DRI — the senolytic peptide.

How FOXO4-DRI targets senescent cells

Compare FOXO4-DRI prices across EU suppliers

Related guides

AHK-Cu

Cortagen

Crystagen